Free Trial
NASDAQ:CLYM

Climb Bio Q1 2025 Earnings Report

Climb Bio logo
$2.31 +0.07 (+3.13%)
As of 09/19/2025 04:00 PM Eastern

Climb Bio EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.15
Beat/Miss
Missed by -$0.16
One Year Ago EPS
N/A

Climb Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Climb Bio Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Climb Bio's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Climb Bio Earnings Headlines

Climb Bio (NASDAQ:CLYM) Upgraded to "Hold" at Wall Street Zen
Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
See More Climb Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Climb Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Climb Bio and other key companies, straight to your email.

About Climb Bio

Climb Bio (NASDAQ:CLYM) Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling. This integrated system enables rapid identification, optimization and high-throughput screening of novel protein candidates, accelerating the transition from target validation to preclinical development while maintaining stringent quality and manufacturability criteria.

Climb Bio has assembled a portfolio of preclinical programs that leverage its platform to generate next-generation biologics in immuno-oncology and related disease areas. The company is advancing these assets through lead optimization and IND-enabling studies, with a view toward first-in-human clinical trials. By focusing on modalities that can modulate immune responses and tumor microenvironments, Climb Bio aims to create differentiated therapeutic candidates with broad applicability.

Headquartered in the greater Boston area, a major hub for life science innovation, Climb Bio operates dedicated research laboratories and maintains a leadership team with extensive experience in biopharmaceutical R&D and strategic partnerships. Looking ahead, the company plans to expand its pipeline through collaborations with academic institutions and industry partners, positioning its platform to address additional disease targets and serve global markets.

View Climb Bio Profile

More Earnings Resources from MarketBeat